Supporting Information

The Natural Products Withaferin A and Withanone From the Medicinal Herb *Withania somnifera* are Covalent Inhibitors of the SARS-CoV-2 Main Protease

Shayantani Chakraborty[‡], Dibyendu Mallick[†], Mausumi Goswami[¥], F. Peter Guengerich[¶],

Anindita Chakrabarty[‡]*, and Goutam Chowdhury[#]*

[‡]Department of Life Science, Shiv Nadar University, Greater Noida, UP, India [†]Department of Chemistry, Presidency University, Kolkata, India

^{*}Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, TN, India

[¶]Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA

[#]Independent Researcher, Greater Noida, UP, India

Contents:

- 1. Figure S1: LC-HRMS spectra of win-Cys, win-GSH, wifA-Cys and wifA-GSH adducts
- Figure S2: LC-MSMS spectra and fragmentation analysis of win-Cys, win-GSH, wifA-Cys and wifA-GSH adducts
- 3. Figure S3: Effect of win and wifA on HepG2 and A549 cells
- 4. Figure S4: Expression and purification of M^{pro}
- 5. Figure S5: Inhibition of protease activity of M^{pro} by wifA
- 6. Figure S6: Non-covalent binding of win-GSH-epoxide and wifA-GSH-epoxide at the active site of the SARS-CoV-2 cysteine protease M^{pro} using *in silico* docking studies.



Figure S1: LC-HRMS spectra of win-Cys, win-GSH, wifA-Cys and wifA-GSH adducts

Figure S2: LC-MSMS spectra and fragmentation analysis of win-Cys, win-GSH, wifA-Cys and wifA-GSH adducts



Figure S3: Effect of win and wifA on HepG2 and A549 cells. A) 2D culture B) Organoid like culture

Α



В

S4

Treatment

Treatment

Figure S4: Expression and purification of M^{pro}. A) Image of a polyacrylamide gel showing the various purified fractions and the purity of isolated M^{pro} B) Image of western blot.



Figure S5: Inhibition of protease activity of M^{pro} by wifA. A. Purified M^{pro} (0.5 μ M) was preincubated for 5-120 min with 5 μ M of wifA before adding the substrate DABCYL-KTSAVLQSGFRKME-EDANS and measuring fluorescence over time B. Purified M^{pro} (0.25 μ M) was preincubated for 5-120 min with 0.5 μ M of wifA before adding the substrate DABCYL-KTSAVLQSGFRKME-EDANS and measuring fluorescence over time C. FRET-based kinetic assay demonstrating the percent inhibition of protease activity of the recombinant M^{pro} (0.5 μ M) following preincubation with an increasing concentration of wifA in the presence of GSH (5 mM). The error bars represent standard deviation of two replicates.





С



Figure S6. Non-covalent binding of win-GSH-epoxide and wifA-GSH-epoxide at the active site of the SARS-CoV-2 cysteine protease M^{pro} using *in silico* docking studies. A) Structures of win-GSH-epoxide and wifA-GSH-epoxide B) Binding parameters of win-GSH-epoxide and wifA-GSH-epoxide at the active site of M^{pro} C-D) Binding of win-GSH-epo-1/2 at the active site of M^{pro} E-F) Binding of wifA-GSH-epo-1/2 at the active site of M^{pro}.

